Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$44.51
-$0.23(-1.55%)
At close: 4:00 PM EST
$44.51
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$12.21 - $45.32
Previous CloseN/A
Volume154.73K
Average Volume (3M)628.22K
Market Cap
$1.23B
Enterprise Value$986.03M
Total Cash (Recent Filing)$248.96M
Total Debt (Recent Filing)$346.45M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Mar 09, 2026EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,688,470
10 Day Avg. Volume469,273
30 Day Avg. Volume628,222
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.30
Price to Sales (P/S)4.12
P/FCF Ratio-2.77
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue5.82
Enterprise Value/Gross Profit59.88
Enterprise Value/Ebitda-215.76
Forecast
1Y Price Target
$68.57Price Target Upside54.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$204.72M
Bulls Say, Bears Say
Bulls Say
Positive Safety ProfileThe safety profile of rosnilimab was tolerable in the UC trial, despite a higher dose than in RA, with no TRSAEs, AEs of liver enzyme elevations, low incidence of injection reactions which was similar to placebo, and no incidence of anaphylaxis or hypersensitivity.
Promising Development PipelineAnaptysBio's development pipeline includes promising assets like rosnilimab and ANB033, with all data timelines on track, showing potential for future advancements.
Strategic Corporate RestructuringAnaptysBio plans to separate its biopharma operations from its high-value royalty assets into two separate, publicly traded companies to ensure maximal value is ascribed to the royalty side of the business.
Bears Say
Legal And Financial RisksIf Anaptys loses or settles unfavorably, the company may face diminished revenue from Jemperli or further legal costs, which could impact the stock price negatively.
Potential Revenue ImpactA worst case scenario would be if GSK wins and receives an irrevocable license to Jemperli and is able to reduce its royalty rates and milestone payments by 50%.
Trial Results ConcernsPhase 2 rosnilimab trial in UC does not meet primary endpoint; T cells likely not a driver of UC pathogenesis.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $45.32 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $1.23B.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Mar 09, 2026 which is in 90 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 04, 2025. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of -$1.214 by $1.734.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is 0.86.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,688,470 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of $0.52 in its last earnings report, beating expectations of -$1.214. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.57 (54.06% Upside)
$68.57 (54.06% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 15.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.44%
12-Months-Change
Fundamentals
Return on Equity
-308.02%
Trailing 12-Months
Asset Growth
-28.44%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio (ANAB) is a clinical-stage biotechnology company focused on the discovery and development of antibody therapeutics for the treatment of various diseases, particularly in the fields of immunology and oncology. The company leverages its proprietary drug discovery platform to create novel therapeutic antibodies aimed at addressing unmet medical needs in conditions such as autoimmune diseases and cancer. AnaptysBio’s pipeline includes several product candidates that are in various stages of clinical trials, showcasing its commitment to advancing innovative treatments.
ANAB Stock 12 Month Forecast
Average Price Target
$68.57
▲(54.06% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---